Sign in
HUMDF Stock Price, Chart, Stats & News
Hua Medicine (Shanghai) Ltd.
Save
Hua Medicine (Shanghai) Ltd. (HUMDF) does not currently pay a dividend.
302.84M
Market cap
–
Current P/E
–
Forward P/E
HUMDF chart
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy.
Similar securities
Based on sector and market capitalization
Report issue